GSK plc has entered an exclusive collaboration with Sino Biopharmaceutical (SBP Group) to promote bepirovirsen, a potential treatment for chronic hepatitis B in China, announced on May 11, 2026. This partnership aims to leverage SBP's access to over 5,000 medical centers to address the health priority of hepatitis B, affecting 75 million people in China.